7 completed, 2 terminated. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 2 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow Myeloma, Plasma-Cell: new trials by email Literature Review of Myeloma, Plasma-Cell trials Research Report on Myeloma, Plasma-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Rimiducid - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2019-06-13 | 2021-09-09 |
| T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2018-09-14 | 2026-06-16 |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Carfilzomib, Daratumumab, Lenalidomide - Myeloma Multiple, Myeloma, Plasma-Cell | Phase 2 | Completed | Tel-Aviv Sourasky Medical Center | 41 | 2018-05-02 | 2022-01-27 |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells - Myeloma, Plasma-Cell, Myeloma-Multiple | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2014-08-12 | 2019-10-08 |
| Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy - Myeloma, Plasma-Cell, Myeloma-Multiple | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 34 | 2010-11-10 | 2019-12-10 |
| Multi-day Doses in Prevention of Nausea and Emesis Palonosetron, Aprepitant, Dexamethasone - Myeloma, Plasma-Cell, Lymphoma, Malignant | Phase 2 | Completed | University of Kansas Medical Center | 20 | 2007-10-01 | 2017-03-09 |
| Phase I/II Study of hLL1 in Multiple Myeloma milatuzumab - Multiple Myeloma, Myeloma, Plasma-Cell | Phase 1 / Phase 2 | Completed | Gilead Sciences | 25 | 2007-01-01 | 2021-08-16 |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Reduced intensity conditioning with allogeneic transplant - Myeloma, Plasma-Cell, Lymphoma, Malignant | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 60 | 2000-03-01 | 2012-08-09 |
Multiple Myeloma (9) · Lymphoma (3) · Neoplasms (2) · Disease Progression (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Nausea (1) · Neoplasms, Plasma Cell (1) · Plasmacytoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Waldenstrom Macroglobulinemia (1)
Blood Protein Disorders (9) · Cardiovascular Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Hemostatic Disorders (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Neoplasms by Histologic Type (9) · Paraproteinemias (9) · Vascular Diseases (9) · Neoplasms, Plasma Cell (8) · Neoplasms (7) · Lymphatic Diseases (3)
Automobiles (3) · Cyclophosphamide (3) · Receptors, Chimeric Antigen (3) · fludarabine (3) · fludarabine phosphate (3) · Dexamethasone (2) · bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine (2) · AP 1903 reagent (1) · Aprepitant (1) · Calcium Dobesilate (1) · Immunotherapy, Adoptive (1) · Lenalidomide (1) · Palonosetron (1) · SLAMF7 protein, human (1) · Transplantation, Homologous (1)
National Cancer Institute (NCI) (4) · Biomea Fusion Inc. (1) · Gilead Sciences (1) · Tel-Aviv Sourasky Medical Center (1) · University of Kansas Medical Center (1) · University of Michigan Rogel Cancer Center (1)
United States (8) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · Spain (1)
James N Kochenderfer, M.D. (3) · John E. Levine, MS MD (1) · Omar Aljitawi, MD (1) · Steve Morris, MD (1) · Steven Z Pavletic, M.D. (1) · William Wegener, MD, PhD (1) · Yael Cohen, MD (1)
PMID 24112026, PMID 26370838, PMID 27412889, PMID 29812997, PMID 33619369, PMID 41702648